C4 Therapeutics (CCCC) Short-term Investments (2020 - 2026)
C4 Therapeutics (CCCC) posted quarterly Short-term Investments of $174.4 million for Q1 2026, up 6.47% year-over-year from $163.8 million in Q1 2025, and little changed quarter-over-quarter from $173.9 million in Q4 2025.
C4 Therapeutics (CCCC) Short-term Investments (2020 - 2026) Analysis & Trends
C4 Therapeutics' Short-term Investments history runs 7 years deep, the most recent figure standing at $174.4 million for Q1 2026.
- In Q1 2026, Short-term Investments rose 6.47% year-over-year to $174.4 million; the TTM figure through Mar 2026 stood at $174.4 million (up 6.47% YoY), while the FY2025 annual figure was $173.9 million, down 8.17% from the prior year.
- Short-term Investments for Q1 2026 stood at $174.4 million, roughly flat from $173.9 million in the prior quarter.
- The five-year high for Short-term Investments was $264.1 million in Q3 2022, with the low at $127.1 million in Q4 2023.
- The 5-year median for Short-term Investments is $189.4 million (2024), against an average of $191.7 million.
- The sharpest annual moves came in 2023 and 2024: Short-term Investments slumped 48.42% in 2023, then surged 49.03% in 2024.
- C4 Therapeutics' Short-term Investments stood at $246.4 million in 2022, then plunged by 48.42% to $127.1 million in 2023, then surged by 49.03% to $189.4 million in 2024, then fell by 8.17% to $173.9 million in 2025, then gained by 0.27% to $174.4 million in 2026.
- Business Quant data shows CCCC's Short-term Investments at $174.4 million in Q1 2026, $173.9 million in Q4 2025, and $133.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 175.05 Mn |
| Mar 31, 2026 | 174.40 Mn |
| Dec 31, 2025 | 173.93 Mn |
| Sep 30, 2025 | 133.08 Mn |
| Jun 30, 2025 | 136.40 Mn |
| Mar 31, 2025 | 163.79 Mn |
| Dec 31, 2024 | 189.41 Mn |
| Sep 30, 2024 | 195.99 Mn |
| Jun 30, 2024 | 190.98 Mn |
| Mar 31, 2024 | 168.53 Mn |
| Dec 31, 2023 | 127.09 Mn |
| Sep 30, 2023 | 155.60 Mn |
| Jun 30, 2023 | 222.40 Mn |
| Mar 31, 2023 | 220.85 Mn |
| Dec 31, 2022 | 246.40 Mn |
| Sep 30, 2022 | 264.10 Mn |
| Jun 30, 2022 | 250.48 Mn |
| Mar 31, 2022 | 245.17 Mn |
| Dec 31, 2021 | 233.16 Mn |
| Sep 30, 2021 | 239.33 Mn |